FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and represents an oncolytic adenoviral vector, a cell and a pharmaceutical composition containing the above vector, as well as applications of the above vectors in preparing a drug for treating cancer in an individual, and to a method of treating cancer in the individual. The presented invention may be used for treating cancer. The oncolytic adenoviral vector contains a nucleic acid skeleton of serotype 5 adenovirus (Ad5), deletion in 24 nucleotides related to amino acids 122-129 in E1A constant region 2, and a nucleic acid sequence coding the human granulocyte-macrophage colony-stimulating factor (GM-CSF) in a site of deleted gp19k/6.7K in the region E3, and capside modification if needed.
EFFECT: invention provides improving the tumour-specific immune response in the individual.
40 cl, 36 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COATED ONCOLYTIC ADENOVIRUS FOR ANTICANCER VACCINES | 2015 |
|
RU2695375C2 |
| ONCOLYTIC ADENOVIRUSES ENCODING BISPECIFIC ANTIBODIES, AS WELL AS METHODS AND APPLICATIONS ASSOCIATED THEREWITH | 2016 |
|
RU2725799C2 |
| EXTENDED ADOPTIVE CELL THERAPY | 2014 |
|
RU2703438C2 |
| GENETIC VECTOR Ad6/3-hTERT-GMCSF CONTAINING GENOMIC SEQUENCES OF RECOMBINANT ADENOVIRUS SEROTYPE 6, HUMAN TELOMERASE PROMOTER, HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE, AS WELL AS FIBER PROTEIN GENE WITH INSERTION OF FIBER KNOB DOMAIN OF ADENOVIRUS SEROTYPE 3 WITH INCREASED TRANSDUCTION INTO TUMOR CELLS | 2023 |
|
RU2814581C1 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
| CHIMERIC ADENOVIRUSES APPLICABLE FOR TREATING MALIGNANT GROWTH | 2005 |
|
RU2448157C2 |
| DESIGNING OF CARCINOLYTIC ADENOVIRUS RECOMBINANT, SPECIFICALLY EXPRESSING IMMUNOMODULATORY FACTOR GM-CSF IN TUMORAL CELLS AND ITS APPLICATION | 2004 |
|
RU2361611C2 |
| ADENOVIRUS CONTAINING ALBUMIN-BINDING SITE | 2015 |
|
RU2711371C2 |
| NEW MEDICAL AGENTS AND USE THEREOF | 2015 |
|
RU2739073C2 |
| MODIFIED ONCOLYTIC ADENO VIRUSES | 2019 |
|
RU2788638C2 |
